Switch studies in virologically suppressed patients

Switch to BIC/FTC/TAF
GS-US-380-1878 Study: Switch to BIC/FTC/TAF
Original article : Daar ES. IDWeek 2017, Abs. LB4
Last update : 11/05/2018

Dr Anton Pozniak
Chelsea and Westminster Hospital
London, UK

  • Switching to BIC/FTC/TAF was non-inferior to remaining on a boosted protease inhibitor + 2 NRTI
    • 1.7% of subjects in each arm had HIV-1 RNA ≥ 50 c/mL through 48 weeks
    • 92.1% of subjects treated with BIC/FTC/TAF maintained virologic suppression vs 88.9% in the continuation arm
  • No treatment emergent resistance in patients who switched to BIC/FTC/TAF
    • 1 subject who continued DRV/r + ABC/3TC developed resistance mutation to ABC
  • BIC/FTC/TAF was well tolerated
    • Adverse events were comparable between arms at week 48
      • mild headache was reported more with BIC/FTC/TAF but was mostly transient and low grade
    • Less than 1% of patients discontinued due to an adverse event in both arms
    • No difference in grade 3 or 4 laboratory abnormalities between arms, except for more total bilirubin abnormalities in continuation arm due to ATV use
    • Statistically significant improvements in triglycerides and total cholesterol:HDL ratio in subjects who switched to BIC/FTC/TAF

Design

Endpoint

  • Primary: proportion of patients with HIV RNA ≥ 50 c/mL at W48 (ITT, snapshot) ; non-inferiority if upper margin of a two-sided 95.002% CI for the difference = 4%

Baseline characteristics and patient disposition

Virologic outcome at W48

  • Patients analysed for resistance: 1 BIC/FTC/TAF vs 3 Continuation ART
  • Emergence of resistance : 0/1 vs 1/3 (L74V in a patient on ABC/3TC + DRV/r)

Adverse events between D0 and W48, %


Median percent change in quantitative proteinuria at W48


UACR: urine albumin:creatinine ratio ; RBP: retinol-binding protein ; β-2- m: beta-2 microglobulin

  • Median change in eGFRCG at W48:
    - 4.3 mL/min BIC/FTC/TAF vs + 0.2 mL/min continuation ART (p < 0.001)

Median Fasting Lipid Changes at Week 48 (mg/ dL )

  • Taking lipid lowering agents at baseline: B/F/TAF : 16.2%, Continuation ART : 15.7%, p = 0.91
  • Initiated lipid lowering agents during the study: B/F/TAF : 2.8%, Continuation ART: 3.5%, p = 0.64
 

Back to Table of Contents

     
     
     
Copyright AEI 2010-2021 | Contact | Faculty and Disclosure | Terms of use | aei